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Dorsal root rhizotomy (DRZ) is currently considered an untreatable injury, resulting in the loss of sensitive function and usually
leading to neuropathic pain. In this context, we recently proposed a new surgical approach to treat DRZ that uses platelet-rich
plasma (PRP) gel to restore the spinal reflex. Success was correlated with the reentry of primary afferents into the spinal cord.
Here, aiming to enhance previous results, cell therapy with bioengineered human embryonic stem cells (hESCs) to overexpress
fibroblast growth factor 2 (FGF2) was combined with PRP. For these experiments, adult female rats were submitted to a
unilateral rhizotomy of the lumbar spinal dorsal roots, which was followed by root repair with PRP gel with or without
bioengineered hESCs. One week after DRZ, the spinal cords were processed to evaluate changes in the glial response (GFAP and
Iba-1) and excitatory synaptic circuits (VGLUT1) by immunofluorescence. Eight weeks postsurgery, the lumbar intumescences
were processed for analysis of the repaired microenvironment by transmission electron microscopy. Spinal reflex recovery was
evaluated by the electronic Von Frey method for eight weeks. The transcript levels for human FGF2 were over 37-fold
higher in the induced hESCs than in the noninduced and the wildtype counterparts. Altogether, the results indicate that
the combination of hESCs with PRP gel promoted substantial and prominent axonal regeneration processes after DRZ.
Thus, the repair of dorsal roots, if done appropriately, may be considered an approach to regain sensory-motor function
after dorsal root axotomy.
1. Introduction
One of the most severe lesions that affects the brachial plexus is
the rupture of nerve roots in their sites of connection to the spi-
nal cord. Although there is still no treatment capable of recov-
ering all lost functions to victims due to the well-known
limited regeneration ability of the central nervous system
(CNS), numerous approaches have been tested for promoting
functional recovery, from advanced surgical techniques to phar-
macological techniques, to overcome this situation [1].
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The physical disconnection of the dorsal roots from the
surface of the spinal cord, as occurs in dorsal rhizotomy
(DRZ), results in a series of cellular and molecular events that
directly affect the sensory pathways [2]. In this case, fibers
with different sensory modalities are unable to reach the spi-
nal cord, leading to significant changes in the spinal circuits
[3, 4] that are also reflected in motor behavior [2]. The major
challenge for recovery techniques is how to allow the primary
afferent fibers to enter the spinal cord environment and form
synapses in specific layers [5], which would then reestablish
the sensory circuits and pathways [6].
In addition to the extensive degeneration of primary
afferent fibers that enter the spinal cord through the dorsal
root, a rapid inflammatory reaction characterized by the pro-
liferation, recruitment, and activation of cells of the nervous
tissue and the immune system occurs in response to lesions
[7]. In this way, the reactive astrocytes and microglia form
a dense nonpermissible wall by joining communicating junc-
tions (the so-called glial scar), creating a physical barrier to
axonal growth [8]. These cells also produce many inflamma-
tory mediators that can have detrimental effects on neuronal
survival and axonal growth, playing an important role in
inhibiting the regeneration of damaged central nervous
axons [9].
Thus, therapies that involve the release of proregenera-
tive molecules, blocking of inhibitory molecules, or providing
growth permissive substrates have been tested and addressed
to augment CNS regeneration with the goal of improving
DRZmanagement [10] for patients with DRZ. Stem cell ther-
apy is one of the most attractive strategies that has been
investigated, and it has already shown positive results regard-
ing regeneration and functional recovery in some experimen-
tal models of lesions and diseases that affect the CNS [11];
these positive impacts are due to multiple advantages that
stem cell therapy can bring to the lesion microenvironment.
The current knowledge suggests that grafted cells can
play their supporting role by delivering trophic factors [12].
It was shown that the effects of cell therapy are mediated by
the secretion of growth factors and/or cytokines that reduce
the process of apoptosis and neuronal inflammation and also
stimulate endogenous regenerative processes, remyelination,
and neural plasticity [12, 13].
In light of the inhibitory and limiting factors of central
regeneration, in this study, we proposed the use of bioengi-
neered human embryonic stem cells (hESCs) that inductively
overexpress human growth factor 2 (FGF2), also known as
basic fibroblast growth factor, which plays an important role
in axonal regeneration after spinal cord injuries [14, 15].
Here, the cells were delivered to the injury site (dorsal rhizot-
omy in a rat model) in an organic 3D matrix formed by
platelet-rich plasma (PRP) gel and were used as a source of
FGF2 and other proregenerative factors. In our previous
work, we standardized the use of PRP gel to treat DRZ, which
reconnected the roots with the spinal surface, and enabled
axonal regeneration. Here, the PRP gel was also used as a
scaffold for hESCs, to potentialize the process of axon
regeneration.
The gel is formed by the combination of platelet-rich
plasma (PRP), serum containing thrombin, and calcium
chloride in the proper volumetric proportions. In turn,
PRP, also known as autologous platelet plasma, platelet-
enriched plasma, or even platelet concentrate [16], is a high
concentration of platelets in a small volume of plasma that
originates from the processing of autologous whole blood
by centrifugation [17]. Once thrombin and calcium chloride
are added to the platelets, PRP forms a gel-like structure that
acts as a biological glue. This chain reaction forms a matrix of
bioactive fibrin with hemostatic and adhesion properties,
mimicking the final steps of the coagulation cascade [18].
Interestingly, platelets, the main component of PRP,
actively participate in the blood clotting process through
the formation of the blood clot [19], and they can also
produce and release a wide range of cell signaling mole-
cules, such as cytokines, trophic factors, and growth fac-
tors that perform many biological actions [20]. Once
PRP is applied on the lesion site as a liquid-to-gel scaffold,
tissue fibrinolysis breaks the fibrin down, releasing the
cocktail of factors with mitogenic and chemotactic proper-
ties from the platelet α-granules, which can be beneficial
to the injured microenvironment.
Therefore, based on the effectiveness of the formed glue
to reconnect spinal roots and the multiple properties of
platelets in the biological microenvironment, as well as
the combined advantages of cytotherapy with stem cells in
regenerative medicine, we proposed the use of platelet-
rich plasma (PRP) gel as a biological glue and as an organic
scaffold for bioengineered hESCs for the treatment of DRZ.
In this way, we hope that this approach opens a new and
alternative front for the treatment of spinal root injuries
and contributes to the future clinical use of this type of
therapy.
2. Materials and Methods
2.1. Experimental Design. In the present study, adult
female Lewis rats (~200 g, 8-10 weeks old) were subjected
to a unilateral rhizotomy (DRZ) of the L4-L6 dorsal roots
and then were divided into the following groups: (a) unle-
sioned/control, (b) DRZ without repair (DRZ), (c) DRZ
followed by root repair with platelet-rich plasma gel
(PRP), and (d) DRZ followed by root repair with PRP
and bioengineered human embryonic stem cells (hESCs).
The animals were obtained from the Multidisciplinary
Center for Biological Investigation (CEMIB/UNICAMP)
and were housed under a 12-hour light/dark cycle with
free access to food and water. All procedures were per-
formed in accordance with the ethical principles regulated
by the National Council of Animal Experimentation
(CONCEA) and with the approval of the Ethics Commit-
tee on Animal Experimentation of the University of Cam-
pinas (CEUA/UNICAMP, protocol no. 4169-1B) and the
Ethics Committee of the School of Medical Sciences of
Unicamp (Campinas; CAAE 78627717.0.0000.5404).
The animals were killed 1 week (acute phase) and 8 weeks
(chronic phase) after establishing lesions, and their lumbar
spinal cords were processed for immunofluorescence and
electron microscopy analysis. Additionally, rats underwent
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8 weeks of behavioral testing (electronic von-Frey), which
was performed weekly (Supplementary Figure S1).
2.2. Human Platelet-Rich Plasma (PRP) Gel. Human
platelet-rich plasma gel was prepared as previously
described [21]. Briefly, PRP gel was obtained by mixing
platelet-rich plasma with serum thrombin, both of which
were isolated from human blood subjected to centrifuga-
tion steps and 10% calcium chloride treatment (complete
methods in the Supplementary Material and Methods).
2.3. Bioengineered Human Embryonic Stem Cells (hESCs).
The cells used in this study were the human embryonic stem
cell line CCTL12, derived at the Masaryk University in Brno,
Czech Republic. The cells were bioengineered for inducible
overexpression of the 18 kDa isoform of human fibroblast
growth factor 2 (FGF2) and then were cultivated for use in
experiments with dorsal rhizotomy (DRZ) in rats. Cells were
engrafted directly at the lesion site as described below, in the
PRP scaffold.
2.3.1. Establishment of Stable Transgenic Cells. Methods for
establishing stable transgenic cells were described in detail
elsewhere [22]. Briefly, EF1a Tet-On 3G system (Clontech®
Laboratories, Cat#631167) was used for the derivation of sta-
ble clones with inducible overexpression. Transfection was
performed with the FuGENE HD Transfection Reagent
(Roche, Switzerland). Positive clones for the Tet-On presence
were transfected with the pTe106 target vector (GenBank
accession number: KX844812), which contains the FGF2-
GFP fusion ORF, where green fluorescent protein (GFP)
was originated from pEGFP-N1 vector (Clontech® Laborato-
ries, Cat#6085-1). Vectors for stable transfections were used
in a linearized form obtained by preparative PCR. Selection
was performed with G-418 at 140μg/mL and blasticidin at
1.2μg/mL, according to the carefully predetermined selec-
tion profiles. Cells were transfected, detached 24 hours post-
transfection, and plated into 6-well plates in serial dilutions.
Selection was carried out for two weeks with regular changes
of medium as described. Induction of the transgene was
achieved by treatment with 1μg/mL doxycycline for 48h.
The resulting stable clone E12-1-1 (inducibly overexpressing
human FGF2 fused with the GFP), which underwent dual
selection, was used in further experiments. The cell karyo-
types were confirmed by the Institut für Humangenetik und
Anthropologie, Jena, Germany.
2.3.2. Culturing. Matrigel-covered plates (Corning Life Sci-
ences, USA) were used for culturing bioengineered hESCs
in monolayers as previously described [23]. The cells were
kept at 37°C under a 5% CO2 atmosphere in mTeSR™1
medium (STEMCELL Technologies™; code 85850), until
they established a monolayer (Figure 1). Doxycycline
(DOX) was added to the medium at a final concentration of
1μg/mL, 48 hours before detachment; DOX induced FGF2
overexpression in the bioengineered hESCs in vitro. After
that, the cells were detached by TrypLE™ Express (Gibco®
by Life Technologies; code 12605-028), collected, washed,
and counted in a Neubauer chamber.
2.3.3. Engrafting. Immediately following DRZ, 3 × 105 hES
cells resuspended in 5μL of mTeSR™1 medium (STEMCELL
Technologies™; code 85850) were engrafted directly at the
lesion site and mixed together with the PRP matrix/scaffold
before its polymerization. To induce overexpression of
FGF2 in hESCs in vivo, DOX was given to animals in combi-
nation with food pellets ad libitum for the whole duration of
the experiment, at a concentration of 625mg of DOX per kg
of food pellets, as described in [24]. Induction was confirmed
by GFP expression in the hESCs.
2.3.4. Phenotyping. Characterization of the pluripotency and
differentiation state of bioengineered human embryonic stem
cells (hESCs) was performed by multicolor flow cytometry
assays using a BD Stemflow™Human andMouse Pluripotent
Stem Cell Analysis Kit in accordance with the manufacturer’s
instructions. The kit contained 3 fluorochrome-conjugated
antibodies for distinguishing pluripotent cells from differen-
tiated cells: (1) Oct3/4 (octamer-binding transcription factor
4), also known as POU5F1, a transcription factor expressed
in pluripotent stem cells; (2) SSEA-1 (stage-specific embry-
onic antigen-1), a differentiation marker in embryonic cells;
and (3) SSEA-4 (stage-specific embryonic antigen-4), which
is a pluripotency marker in embryonic cells.
2.3.5. Gene Expression. The relative mRNA levels of FGF2,
BDNF, and GDNF genes in the in vitro bioengineered human
embryonic stem cells were evaluated by qRT-PCR. These
cells were divided into 4 groups: wildtype hESCs; wildtype
hESCs + DOX; bioengineered hESCs; and bioengineered
hESCs + DOX. Each group was analyzed in triplicates of
1:8 × 10−6 cells. Total RNA was extracted from cells, 48 hours
after activation by doxycycline, using an RNeasy Lipid Tissue
Mini Kit (cat. no. 74804, Qiagen) according to the manufac-
turer’s instructions. The quantity, quality, and integrity of the
RNA samples were determined using a nanophotometer and
agarose gel electrophoresis under denaturing conditions. A
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems: 4368814) was employed to convert 2μg of total
RNA into cDNA, which was used in triplicate as a template
for PCR reaction. qRT-PCR was performed with an
Mx3005P instrument (Agilent Technologies, Santa Clara,
CA, USA), with the TaqMan Gene Expression Master Mix
(2x) (Life Technologies: PN 4369016) and TaqMan
reagents (Table 1) in a volume of 20μL. The following ther-
mocycling conditions were used: 45 cycles for amplification
(95°C for 10 minutes, followed by 95°C for 15 seconds and
60°C for 1 minute).The 2−ΔΔCt method [25] was performed
for relative quantification, and GAPDH was used as the
housekeeping gene.
2.4. Dorsal Rhizotomy and Repair.Animals were anesthetized
by a combination of xylazine chlorhydrate (Anasedan®,
10mg/kg, Sespo Indústria e Comércio, Paulínia, SP, Brazil)
and ketamine hydrochloride (Dopalen®, 50mg/kg, Sespo
Indústria e Comércio, Paulínia, SP, Brazil) and then were
subjected to unilateral spinal dorsal rhizotomy of the dor-
sal roots, which was performed based on the protocols of
a previous work [21, 26]. Lesions were generated on the
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right side of the L4, L5, and L6 lumbar dorsal roots after lami-
nectomy. A longitudinal incision was made to open the dural
sac, and the dorsal roots associated with the lumbar intumes-
cence were identified and cut 2mm from the surface of the spi-
nal cord with microscissors (Figures 2(a)–2(c)).
In the treatment groups, the roots were replaced at the
exact point of detachment, on the dorsal surface of the lum-
bar spinal cord at the lesion site with the aid of the PRP gel
(Figure 2(c)). For this procedure, during surgical repair of
the lesioned roots, the components to activate PRP were
mixed in an Eppendorf© tube at the following concentra-
tions: 30 μL of PRP + 2:625 μL of autologous serum + 0:875
μL of 10%calcium chloride. Then, the mixture was applied
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Figure 1: (a–c) Cultivation of bioengineered human embryonic stem cell (hESC) clones over time. The formation of the cell monolayer
(confluence) was observed on the fifth day (c). The cells were attached to a matrix (Matrigel) and expanded rapidly in their own medium,
and they formed colonies and/or aggregates. Bright field. Scale bar = 10 μm. (d) Clones were induced to overexpress FGF2 at 48 hours after
doxycycline administration. Practically all cells were fluorescent green (GFP+), which indicates that hESCs were activated by DOX and
then overexpressed FGF2. Phase contrast. Scale bar = 25 μm. (e) A single bioengineered hESC was observed under electron microscopy,
enabling visualization of the large nucleus, very evident nucleolus, and euchromatin, indicating high metabolic activity. Scale bar = 1 μm.
(f–h) Relative expression of basic fibroblast growth factor (FGF2), brain-derived neurotrophic factor (BDNF), and glial cell line-derived
neurotrophic factor (GDNF) mRNA in vitro. (f) The transcript levels for FGF2 were over 35-fold higher when modified hESCs were
induced by doxycycline. Modified hESCs not treated with doxycycline and wildtype cells treated or not treated with doxycycline presented
nearly undetectable expression of FGF2. (g) Compared with other groups, the transcript levels for BDNF were significantly higher when
modified hESCs were induced by doxycycline. (h) The transcript levels for GDNF were not significantly different between groups. Mean ±
SEM. ∗∗∗p < 0:001. hESCs: human embryonic stem cells; WT: wildtype; DOX: doxycycline.
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lesion was created. Then, the lesioned roots were returned to
their original sites. Additionally, in the PRP + cell groups, 3
× 105 hESCs were added to the activated PRP, at the moment
of repair.
After the surgical procedures, the muscle fascia and skin
were sutured in layers. The animals were housed under a
12 h light/dark cycle and controlled temperature with free
access to food and water for a period of up to 8 weeks. Tram-
adol chlorhydrate (Germed Farmacêutica Ltda, Hortolândia,
SP, Brazil) was administered after the surgical procedure
(20mg/kg, by gavage) for 5 days (2.5mg/day, dissolved in
drinking water).
2.5. Functional Analysis-Reflex Arc Evaluation (Von Frey).
The animals were individually placed in acrylic boxes with
a wire grid floor (10 × 10 × 20 cm) with a tilted mirror below
them, to provide a view of the hind paws. After habituation, a
gradual increasing pressure was applied on the central plan-
tar area of the right hind paw with a 0.5mm2 polypropylene
tip coupled to a handheld force transducer (electronic
anesthesiometer, EFF 301 by Insight, Ribeirão Preto, Brazil),
evoking flexion reflex and paw withdrawal. Pressure intensity
was automatically recorded three times for each animal, with
an interval of approximately 10 minutes between each mea-
surement. The maximum pressure limit established was
80 g. If the animal did not respond to this intensity of pres-
sure, it was considered to exhibit total paw anesthesia. The
reflex paw flinches are shown as the mean ± standard error
of themean (SEM) of the weekly measurements.
2.6. Specimen Preparation. Animals were anesthetized by an
overdose of a combination of xylazine chlorhydrate (Anase-
dan®, 10mg/kg, Sespo Indústria e Comércio, Paulínia, SP,
Brazil) and ketamine hydrochloride (Dopalen®, 50mg/kg,
Sespo Indústria e Comércio, Paulínia, SP, Brazil), and the
vascular system was rinsed by transcardial perfusion with
cold 0.1M saline phosphate buffer (PBS; pH7.38), which
was followed by a rinse with a fixative solution.
For immunofluorescence analysis, the rats were killed 1
or 8 weeks after DRZ. After perfusion with PBS, the tissues
were fixed by vascular perfusion with 4% paraformaldehyde
in phosphate buffer (PB 0.1M, pH7.38). The lesioned
region of the spinal cord was exposed, dissected, and post-
fixed overnight at 4°C in the same fixative solution, and
then they were subjected to gradually increased concentra-
tions of sucrose (10%, 20%, and 30% sucrose in 0.1M
sodium phosphate buffer, 24 h in each solution) before
freezing. The specimens were embedded into Tissue-Tek®
O.C.T. (Sakura Finetek USA, Inc., Torrance, CA USA)
and were frozen at -40°C. Transverse sections (12μm
thick) were obtained with a cryostat (Microm HM 525®,
Microm International GmbH, Walldorf, Germany), and
then they were transferred to gelatin-coated slides and
dried at room temperature for 30 minutes; then, they were
stored at -20°C until immunolabeling was performed.
For electron microscopy analysis, the rats were killed 8
weeks after DRZ surgery. After perfusion with PBS, the
tissues were fixed by vascular perfusion with 2.5% glutaral-
dehyde and 1% paraformaldehyde in phosphate buffer (PB
0.1M, pH7.38). The lesioned region of the spinal cord was
exposed, dissected, and fixed for 24 hours at 4°C in the
same fixative solution. The samples were then trimmed
and postfixed in 1% osmium tetroxide solution in phos-
phate buffer (PB 0.1M, pH7.38). After postfixation, the
samples were washed in distilled water, dehydrated
through treatment with a graded ethanol series and ace-
tone, and then embedded in Durcupan ACM (Fluka,
Steinheim, Switzerland).
2.7. Immunofluorescence. Transverse sections of the spinal
cord were allowed to come to room temperature, washed
twice with 0.01M phosphate buffer (PB) (pH7.4), blocked
with blocking solution for 45 minutes, and incubated with
primary antibodies for 4 hours in a humid chamber at room
temperature. After rinsing with 0.01M PB (pH7.4), samples
were incubated with secondary antibodies and then they
were washed twice with 0.01M PB (pH7.4). Primary and sec-
ondary antibodies are indicated in Table 2. Slides were
mounted with coverslips on glycerol solution (glycerin and
distilled water, 3 : 1) containing 4′,6-diamidine-2′-pheny-
lindole dihydrochloride (DAPI, DNA dye, 1 : 1000), and then
were observed under a fluorescence microscope (Leica
DM5500 B microscope) coupled with a Leica DFC345 FX
camera (Leica Microsystems CMS GmbH). For primary anti-
bodies, the blocking solution was prepared with 3% bovine
serum albumin solution in 0.1M PB (pH7.38), while the
antibody dilution solution (for primary and secondary anti-
bodies) was prepared with 1% BSA and 2% Triton X in
0.1M PB (pH7.4).
For quantitative measurements, three representative
images of the spinal cord (L4-L6) of each animal were
captured at a final magnification of 200x. The integrated
density of pixels (IDP), which represents the intensity of
labeling, was measured utilizing ImageJ software (version
1.45s, National Institute of Health, USA). The data are repre-
sented as the mean ± standard error of themean (SEM) for
each group.
2.8. Transmission Electron Microscopy (TEM). Trimmed
blocks were cut in an ultramicrotome (Leica Ultracut UCT
Ultramicrotome), and semithin transverse sections (0.5μm)
were obtained and stained with 0.25% toluidine blue for light
microscopy observation. Then, ultrathin transverse sections
(70 nm) from the L4 to L6 segments were made in the same
ultramicrotome (Leica Ultracut UCT Ultramicrotome),
collected on formvar-coated single-slot grids, and then
contrasted with uranyl acetate (2%) and lead citrate. Finally,
the ultrathin transverse sections (70 nm) were examined
under a Tecnai G2 Spirit BioTwin (FEI, Eindhoven, The























Figure 2: (a–c) Region of lumbar intumescence of an injury in a rat, seen through a surgical magnifying loupe. (a) Intact dorsal roots (L4, L5,
and L6). (b) Transected dorsal roots (L4, L5, and L6). (c) PRP gel on the transected dorsal roots (L4, L5, and L6), immediately after its
application. Immediately after applying the gel, it started to polymerize. From then on, it was no longer possible to reposition the roots
that were transected on the spinal surface. Therefore, the repositioning of the roots after injury must be accurate before applying the gel. It
is also possible to observe some hemorrhage after the lesion induction, where it was stopped with the gel. Scale bar = 5mm. (d)
Representative photomicrograph of transverse sections of the spinal cord stained with Sudan black 8 weeks after DRZ. The lesioned
ipsilateral root was completely degenerated, as opposed to the contralateral root, which exhibits high integrity. Scale bar = 100μm. (e–g)
Photomicrograph of transverse sections of the hemispinal cord stained with toluidine blue, 8 weeks after the DRZ. (e) The unlesioned root
showed a large number of axons. (f) The lesioned root was completely disrupted. (g) The repaired root showed a significant number of
axons. Scale bar = 100 μm. (h–j) Bioengineered human embryonic stem cells (hESCs) found in the roots repaired with PRP, two weeks
after injury: (h) hESCs overexpressing FGF2 (GFP+), in green; (i) hESCs marked with an antibody specific for human mitochondria
(hMito), in red; (j) merge: GFP+ (green) + hMito (red), demonstrating that the engrafted cells are in fact the modified bioengineered
hESCs. In blue, nuclear DNA labeling was performed using DAPI. ∗Repaired root. ∗∗Spinal cord. The cells remained in the replanted root.
Scale bar = 20μm.
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Netherlands) transmission electron microscope, to evaluate
structural and morphological changes in the microenviron-
ment and adjacent areas 8 weeks after dorsal rhizotomy
(chronic phase) and repair.
2.9. Statistical Analysis. Data analysis was performed with
GraphPad Prism (version 7.00 for Windows, GraphPad Soft-
ware, La Jolla, California, USA). Immunofluorescence and
qRT-PCR data were evaluated via one-way ANOVA
followed by Bonferroni multiple comparisons test. Data from
the functional analysis (Von Frey) were evaluated via two-
way ANOVA followed by Bonferroni Multiple Comparison
Test. The data are presented as the mean ± standard error
of mean (SEM) and the differences between groups were
considered significant when the p value was >0.05 (∗),
>0.01 (∗∗), or >0.001 (∗∗∗).
3. Results
3.1. Dorsal Rhizotomy Overview. After DRZ, many structural
and morphological changes in the spinal cord microenviron-
ment and roots could be observed. The lesion had an ampli-
tude that covered a large part of the dorsal columns and
funiculus. In this model, 8 weeks after lesion induction, it
was possible to report the absence of the ipsilateral dorsal
root (L4-L6), which was completely degenerated as a result
of the lesion. Also, an intense demyelination and degenera-
tion in the site of injury and adjacent areas was depicted,
resulting in a large reduction in sensory fibers. No changes
were noticed in the contralateral dorsal root. Additionally,
there was a large number of infiltrated cells at the lesion site
(which could be seen in the immunofluorescence analyses
and were mostly macrophages). Figures 2(d)–2(g) show a
spinal cord, 8 weeks after dorsal rhizotomy that demon-
strates some of these changes in comparison with a repaired
spinal cord.
3.2. Characterization of Platelet-Rich Plasma Gel. The three-
dimensional mesh (Supplementary Figure S1) formed from
the volumetric proportions of PRP, thrombin, and calcium
chloride defined here was similar to the medium fibers that
were described by Perez et al. [27]. Gel fibers of this caliber
allowed the regenerating axons to pass through the gel and
reach the spinal cord. In addition, they also served as
scaffolds for the cells, where the cells were “trapped” within
the fibers of the gel. Thin fibers would not provide structure
for the cells, while thick fibers would prevent axons from
entering the spine.
3.3. Bioengineered hESC Phenotyping by Flow Cytometry.
Characterization of the cellular pluripotency and differentia-
tion state of bioengineered human embryonic stem cells
(hESCs) was performed by flow cytometry assays using a
BD Stemflow™ Human and Mouse Pluripotent Stem Cell
Analysis Kit. Approximately 97.9% of the bioengineered
hESCs expressed SSEA-4, 60.6% expressed Oct3/4, and 0.1%
expressed SSEA-1 (Supplementary Figure S2). Thus, the
analysis allowed us to define an undifferentiated pluripotent
human embryonic stem cell population. In addition, the
sample was a homogeneous population regarding size and
granularity. Additionally, isotype controls were used to
identify any nonspecific (background) labeling by specific
antibodies present in the kit (Supplementary Figure S3).
3.4. Gene Expression in Bioengineered hESCs Characterized
by qRT-PCR. Relative mRNA levels of the FGF2, BDNF,
and GDNF genes in hESCs in vitro were evaluated by qRT-
PCR. The normalized quantification of the transcripts for
FGF2, BDNF, and GDNF is shown in arbitrary units and
confirmed that both wildtype and bioengineered cells
expressed the genes of interest, regardless of whether they
were induced with doxycycline (see Figures 1(f)–1(h)). The
degree of FGF2 transcription was approximately two orders
of magnitude higher in the induced hESCs than in the nonin-
duced and wildtype counterparts, highlighting that bioengi-
neered hESCs induced with doxycycline overexpressed
FGF2. These data demonstrate that hESCs can be bioengi-
neered to produce lines with the properties needed for the
nervous regeneration process. Additionally, BDNF gene
expression was significantly higher in the bioengineered cell
group than it was in the other groups. GDNF gene expression
did not show significant differences between groups.
3.5. Fate of Bioengineered hESCs after Engrafting. After
engraftment of the bioengineered hESCs (in the PRP scaf-
fold) directly at the DRZ site, the site was analyzed two weeks
after injury (during which the inducer DOX was supplied to
animals via food pellets). GFP-positive cells were observed at
the injury site, especially in the repaired dorsal root (see
Figures 2(h)–2(j)). Immunolabeling of anti-human mito-
chondria confirmed the presence of human cells.
3.6. Reflex Arc Evaluation by Electronic Von Frey. The reflex
arc was measured weekly by the electronic Von Frey test.
As shown in Figure 3, there were many significant differences
between groups during the test. Overall, the PRP gel + hESC
group had the best improvements, followed by the group of
Table 2: Antibodies used in the immunofluorescence assay.
Target Host Conjugate Dilution Manufacturer Cat. code
VGLUT1 Rabbit — 1/1000 Synaptic systems 135303
GFAP Rabbit — 1/1500 Abcam AB7260
Iba-1 Rabbit — 1/750 Wako 019-19741
CGRP Rabbit — 1/1000 Sigma C8198
Rabbit IgG Donkey CY2 1/500 Jackson 711-225-152
Rabbit IgG Donkey CY3 1/500 Jackson 711-165-152
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the PRP gel without cells, while there was no response in the
DRZ group. Moreover, one week after causing the lesion, it
was observed that animals from the DRZ group presented
total anesthesia of the ipsilateral hind paw, exhibiting no
flinch response (score 80 grams). This result was consistent
over the 8 weeks of analysis. On the other hand, the measures
of the animals from the repaired groups gradually improved,
indicating partial recovery of the reflex arc over time.
Although there was no significant difference between the
repair treatment groups in the last week of analysis, at some
experimental times, the PRP gel + hESCs group had the best
performance, approaching that of the control group. In turn,
the animals in the control group (unlesioned) responded to
the tactile stimulus (with a flinch response of approximately
35 grams) at all experimental times of analysis. We empha-
size that exaggerated reactions that may suggest allodynia
or hyperalgesia were not observed in any of the groups.
3.7. Immunofluorescence. Quantitative measurements of
VGLUT1 (to detect glutamatergic synaptic changes), GFAP
(to detect astroglial reactivity) and Iba-1 (to detect microglial
reactivity) immunoreactivity in the spinal cord after rhizot-
omy and repair were carried out 1 (acute phase) week after
lesion induction. Qualitative images of CGRP-positive fibers
were also analyzed 1 week after lesion and repair. Represen-
tative immunofluorescence images of the lesioned side of
the spinal cord are shown in Figures 4–6.
3.8. Glutamatergic Synapses. Intense VGLUT1 immunolabel-
ing on the contralateral side was observed in all experimental
animals, which was attributed to the large number of inputs
to the contralateral neurons compared to those on the
lesioned side. In contrast, the immunostaining showed lower
synaptic density on the ipsilateral side in all experimental
groups—except the control group (unlesioned)—confirming
the outcomes of the surgical procedure (the loss of primary
afferents), 1 week after lesion induction (Figure 4, Table 3).
However, it was possible to observe an increase in punctate
labeling, after root repair by PRP, which was statistically sig-
nificant in the hESC group in comparison to the DRZ group.
This is an important finding of the present study and suggests
that root repair with the PRP gel enabled the reentry of fibers
into the spinal cord and hESCs may enhance the regenera-
tion of primary afferents.
3.9. Astrogliosis. Immunolabeling for GFAP demonstrated a
significant increase in astrocyte activity after lesion induc-
tion, as demonstrated by the presence of GFAP-positive acti-
vated astrocytes in the spinal superficial dorsal laminae in all
experimental groups—except for the control group (unle-
sioned), which showed a low reactivity for GFAP
(Figures 5(a), 5(c), 5(e), and 5(g)). However, the astroglial
reactivity was not significantly further increased after human
PRP gel application or hESC engrafting, 1 week after lesion
induction: control = 115:99 ± 9:04; DRZ = 678:65 ± 10:64;
PRP gel = 701:15 ± 13:02; and PRP gel + hESCs = 680:02 ±
5:46. Relative immunoreactivity from the ipsilateral side is
expressed as the mean ± standard error of the mean of the
density of pixels; n = 5 per group.
3.10. Microgliosis. Similar results were observed in micro-
glial reactivity. A significant increase in microglial activity
after lesion induction was observed as evidenced by Iba-1
immunostaining in the spinal superficial dorsal laminae
in all experimental groups, except for the control group
(unlesioned), which showed low reactivity for Iba-1
(Figures 5(b), 5(d), 5(f), and 5(h)). Once again, the microglial
reactivity was not significantly further increased after human
PRP gel application or hESC engrafting, 1 week after lesion
induction: control = 58:63 ± 12:75; DRZ = 445:19 ± 7:19;
PRP gel = 451:37 ± 11:50; and PRP gel + hESCs = 443:52 ±
12:35. Relative immunoreactivity from the ipsilateral side is
expressed as the mean ± standard error of themean of the
density of pixels; n = 5 per group. These are also important
findings because the nonexacerbation of glial reactivity may
Electronic von-Frey test





























Figure 3: Electronic Von Frey measurements (mean values) obtained from the right hind paw (lesioned). The values are shown as the grams
applied to trigger the “flinch” response. Statistical differences among groups are indicated with asterisks in addition to the graph. ∗p < 0:05;
∗∗p < 0:01; ∗∗∗p < 0:001. Only the groups that underwent root repair with the PRP gel demonstrated the recovery of sensitivity to tactile
stimulation. Further, the PRP gel + hESC group had the best performance in the whole experiment.
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have facilitated the penetration of regenerating axons into the
spinal surface.
3.11. CGRP-Positive Fibers. There was a high density of fibers
exhibiting CGRP immunoreactivity in the control group
(unlesioned) in the dorsal horn of the spinal cord in laminae
I and II, and there was a lower density of these fibers in lam-
ina V. CGRP-like immunoreactivity was also localized in
motoneurons of the ventral horn (Figure 6). However, com-
pared to the control results, immunostaining showed lower
immunoreactivity on the ipsilateral side after DRZ in all ana-
lyzed spinal laminae, especially in the superficial laminae.
In contrast, an increase in CGRP-immunoreactivity was
observed in the hESC group in comparison to that of the
DRZ group. We emphasize that there was no increase in


























































































































Figure 4: Representative immunofluorescence micrographs of VGLUT1 (glutamatergic synapses) immunolabeling on the ipsilateral side of
the spinal cord after rhizotomy and repair, 1 week after lesion induction. A significant decrease in glutamatergic synaptic density was observed
following DRZ. However, the “hESC” group showed great improvement in punctate labeling in comparison to the DRZ group. Scale bar =
50μm.
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to the unlesioned animal, which corroborates the lack of
observed hypersensitivity.
3.12. Transmission Electron Microscopy (TEM). Through
transmission electron microscopy (TEM), it was possible to
investigate morphological and structural aspects of the dorsal
root repair with the PRP gel, exploring the reconnected root
and spinal microenvironment, 8 weeks after lesion induction
when the molecular changes were confirmed.
As seen in Figure 7, which corresponds to an assembly of
representative TEM photomicrographs, it is possible to
observe the presence of the repaired dorsal root at the spinal
surface of the lesion site, presenting a large number of mye-
linated axons (blue arrow) grouped into small fascicles, blood
vessels (red arrow), and many Schwann cells (purple
arrow)—being a strong indication of the repaired root’s func-
tionality, providing physical support for recovery.
4. Discussion
A reproducible model for investigating the regeneration of
sensory pathways and the consequences of their absence is
the dorsal rhizotomy (DRZ) at the lumbar level in rats, which
is an important source of information for preclinical studies
of injuries at the interface between the CNS and PNS [28].
The DRZ affects the central projections of the axons of sen-
sory neurons present in the dorsal ganglia, disconnecting
them from the spinal cord surface in the dorsal column and
imparting partial or complete loss of sensitivity in the
affected limb. These losses can be present for a long time or
can even become permanent, and they were observed in the
“DRZ” group in the morphological analysis and in the func-
tional test.
As a result of the lesion, glutamatergic (VGLUT1) synap-
ses are lost and reorganized, resulting in the disappearance of
specific synaptic clusters [29]. Therefore, through different
histological techniques, it was possible to assert that the
experimental model used here resulted in the withdrawal of
primary afferents. The evidence for this was the extensive
degeneration in the dorsal column of the spinal cord and a
concomitant decrease in immunoreactivity for VGLUT1,
which mainly occurred in the superficial laminae and was
accompanied by an intense reactivity of glial cells. Microglial
reactivity is related to the removal of VGLUT1 synapses in
the ventral horn, while such loss mechanism is microglia-
independent for the dorsal horn [29]. These morphological
changes were reflected in functional behavior, resulting in
the loss of sensibility in the ipsilateral site to the lesion site.
To reverse or minimize this scenario and to achieve func-
tional recovery, the present study proposed the use of
platelet-rich plasma (PRP) gel as an adhesive element for
reconnecting the dorsal roots to the spinal cord surface (act-
ing as a biological glue for structural repair) and as a scaffold
for bioengineered human embryonic stem cells (hESCs). It is
important to highlight that the right biological scaffold needs
to provide structural integrity for cells. Therefore, the scaffold
should be highly porous and should have pores of a suitable
size because released factors are important for stem cell seed-
ing, migration, and nutrient supply [30]. In this sense, the
PRP scaffold proved to be suitable for such applications.
Currently, the use of platelet-rich plasma (PRP), in its liq-
uid or gel form, extends to a wide range of surgical proce-
dures, and there are several studies that have demonstrated
the benefits of using PRP in treating a wide spectrum of inju-
ries. Another platelet-rich blood derivative that has been
used in regenerative medicine is Choukroun’s platelet-rich
fibrin [31]. PRF consists of a leukocyte-platelet-rich dense
fibrin matrix with cytokines, platelets, and blood stem cells
combined altogether [32]. This biomaterial can act as a
proper scaffold for cells, and it is capable of releasing higher
quantities of growth factors compared to PRP [33, 34], prop-
erties that permit the crescent use of both PRF and PRP in
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Figure 5: Representative immunofluorescence micrographs of
GFAP (astrocytes) and Iba-1 (microglia) immunolabeling on the
ipsilateral side of the spinal dorsal superficial laminae after lesion
rhizotomy and repair. A significant increase in glial reactivity was
observed after lesion induction. However, neither human PRP gel
application nor hESC engrafting exacerbated glial reactivity, in
comparison to the DRZ group. These findings directly reflected in
the functional recovery from these groups. Scale bar = 50μm.
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Despite the good potential of PRF as a nerve guidance
conduit [36], the reported benefits of PRF in nervous system
injury treatment are still moderate [37, 38]. In the context of
nervous system disorders, the benefits of PRP already
described in recent literature involve neuroprotection and
prevention of apoptosis, mediation of neuroinflammation,
and stimulation of angiogenesis and axonal regeneration
[39]. Additionally, it is important to note that the present
study is aimed at analyzing the modified hESC contribution

























Figure 6: Representative immunofluorescence micrographs of CGRP immunolabeling on the ipsilateral side of the spinal cord after
rhizotomy and repair, 1 week after lesion. Similar to VGLUT1 immunolabeling, a significant decrease in CGRP immunoreactivity was
observed following DRZ. However, the “hESC” group showed a great improvement in CGRP-positive fibers in comparison to that of the
DRZ group. Scale bar = 50 μm.
Table 3: Immunoreactivity related to synaptic vesicles containing the vesicular glutamate transporter type 1 (VGLUT1) (ipsi/contralateral
ratio) was obtained by measuring the integrated density of pixels in the spinal cord in III, V, and VI and IX laminae, 1 week after
rhizotomy and repair of dorsal nerve roots (mean ± standard error of mean).
Laminae Control DRZ PRP gel hESCs + PRP gel
III 1:08 ± 0:15 0:23 ± 0:11 0:40 ± 0:12 0:54 ± 0:15
V and VI 1:11 ± 0:15 0:13 ± 0:07 0:29 ± 0:11 0:35 ± 0:08
IX 1:03 ± 0:10 0:10 ± 0:05 0:23 ± 0:09 0:27 ± 0:13
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In parallel, to enhance nerve regeneration and make it
even more efficient, several studies have explored the
potential of different cell therapy strategies for the treat-
ment of a wide spectrum of diseases and injuries in the
central nervous system (CNS) [11, 40, 41]. These cells
have important characteristics that make them useful in
the regenerative process, such as their capacity for self-
renewal [40], as well as their angiogenic, antiapoptotic,
anti-inflammatory, and immunomodulatory properties
[12, 41]. These properties are enabled by the production
of different trophic factors and cytokines [11], according
to their respective origin (tissue source) and the stimulus
they received. The stem cells can be used as progenitors
of differentiated cells transplanted to injury sites (reposi-
tion therapy) or as a source of trophic molecules that con-
tributes to tissue regeneration [40]. Nowadays, both
applications have been explored in translational regenera-
tive medicine especially due to a crescent understanding
of molecular mechanisms related to therapeutic effects of
























Figure 7: Representative transmission electronic micrographs of the repaired root and spinal cord dorsal horn (superficial region), 8 weeks
after dorsal rhizotomy (DRZ) and repair with PRP gel. The extent of the repaired root can be observed with a significant number of
myelinated axons (blue arrow), blood vessels (red arrow), and many Schwann cells (purple arrow). The image also highlights the subtle
boundary between PNS/CNS clearly delimited by the dorsal root transition zone (DREZ), which contains central and peripheral nervous
tissue. Moreover, proximal to the DREZ, myelin sheaths formed by oligodendrocytes can be observed, while further from the DREZ, the
sheaths are formed by Schwann cells and wrapped the endoneurium. Their presence on the spinal surface of the root repaired in these
morphological and structural conditions is one of the requirements for functional recovery.
12 Stem Cells International
a promising source of growth factors. In this context, we
employed hESCs overexpressing FGF2, due to their acces-
sibility to undergo genetic modifications while retaining
the pluripotency [43].
Here, the PRP gel used in combination with cell therapy
contributed to axon regeneration and the nonexacerbation
of glial reactivity (which may have facilitated the penetration
of regenerating axons) in the analyzed spinal cord laminae, as
well as by the positive results in a functional test. We believe
that these regenerative improvements have three causes: root
repair itself, the intrinsic action of platelets, and the produc-
tion of factors by hESCs, especially FGF2.
Regarding the first cause, the PRP gel allowed the
physical reconnection of the lesioned root to the surface
of the spinal cord, allowing the reentry of fibers. There-
fore, a large number of axons were observed inside the
repaired root, which contributed to the restoration of the
reflex arc. It is known that root repair alone is neuropro-
tective and allows axonal regeneration [44–46]. Important
studies have observed greater survival of motoneurons in
cases of ventral root repair [47], while other studies [26]
have observed improved recovery of primary fibers in
cases using dorsal root repair. The authors suggest that
the repaired root increases the production of neurotrophic
factors and that the persistent opening of the blood-brain
barrier (BBB) allows trophic substances to stimulate the
regeneration of axons.
Secondly, the platelet biology itself may have favored
the improvement of the lesioned microenvironment. Specif-
ically, the PRP gel is biodegraded over time and a wide
range of molecules are released by the platelets’ granules.
As an example, granules release cytokines, as well as tro-
phic and growth factors, including platelet-derived growth
factor (PDGF), transforming growth factor-β (TGF-β), vas-
cular endothelial growth factor (VEGF), growth factor basic
fibroblasts (bFGF), insulin-like growth factor (IGF-1),
hepatocyte growth factor (HGF), and epidermal growth fac-
tor (EGF) [48, 49]. These molecules can even regulate the
biological effects of other growth factors such as nerve
growth factor (NGF) and brain-derived neurotrophic factor
(BDNF) [20]. Together, these factors play a significant role
in tissue regeneration, regulating and mediating prolifera-
tion, allowing cell differentiation stimulating angiogenesis,
and neuroprotection [48].
Lastly, it is also known that trophic factors produced by
stem cells (such as BDNF and GDNF by bioengineered
hESCs) mediate survival, differentiation, growth of neurites,
and functional plasticity in the central and peripheral ner-
vous system. In addition, they play a crucial role in maintain-
ing the specific functions of distinct populations of neurons,
not only in development, but also after spinal cord and nerve
injuries [15, 50]. In addition, FGF2 overexpression by bioen-
gineered hESCs may facilitate neuronal repair, since several
experimental studies in the CNS and PNS have revealed that
this growth factor plays an important role in neuronal axonal
regeneration and repair after brain injuries [51] and spinal
cord injuries [14, 15].
In spinal cord injuries, functional recovery is attributed
to FGF-mediated promotion of neuronal survival [52–54],
reduction of glial reactivity [14], and stimulation of angio-
genesis [55], which results in a reduction in the lesion volume
[56]. FGF2 is also capable of stimulating synaptic plasticity
[57–59]. Most likely, after cell engraftment, the expression
of trophic factors increases, due to stimulation of the micro-
environment, which may be responsible for the regenerative
improvements observed in the hESC group.
Nevertheless, it is important to highlight that the thera-
peutic approach used herein seems to allow oriented axonal
regeneration, since there was no aberrant sprouting of regen-
erated fibers, and ectopic expression of VGLUT1 and CGRP.
Thus, we could not detect signs of allodynia nor hyperalgesia.
5. Conclusion
Overall, the results of the present study indicate that the dor-
sal root repair performed with the support of platelet-rich
plasma (PRP) gel contributed to axonal regeneration after
dorsal rhizotomy, as seen by the histological and functional
observations. In addition, the bioengineered human embry-
onic stem cell (hESC) therapy further enhanced the axonal
regeneration process after root repair. Therefore, our data
support the idea that early root reconnection, combined with
the engrafting of bioengineered stem cells is effective, open-
ing new possibilities in translational medicine.
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